-
Something wrong with this record ?
Inhibition of topoisomerase IIα: novel function of wedelolactone
Petr Benes, Lucia Knopfova, Filip Trcka, Alice Nemajerova, Diana Pinheiro, Karel Soucek, Miroslav Fojta, Jan Smarda
Language English Country Ireland
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
NS9600
MZ0
CEP Register
- MeSH
- Antigens, Neoplasm metabolism MeSH
- Apoptosis drug effects MeSH
- Cell Cycle drug effects MeSH
- Cell Growth Processes drug effects MeSH
- DNA-Binding Proteins antagonists & inhibitors metabolism MeSH
- DNA Topoisomerases, Type II metabolism MeSH
- Enzyme-Linked Immunosorbent Assay MeSH
- Immunoblotting MeSH
- Topoisomerase Inhibitors pharmacology MeSH
- Coumarins pharmacology MeSH
- Humans MeSH
- Cell Line, Tumor MeSH
- Breast Neoplasms drug therapy enzymology pathology MeSH
- DNA Damage MeSH
- Antineoplastic Agents pharmacology MeSH
- Signal Transduction MeSH
- Cell Survival drug effects MeSH
- Check Tag
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
The naturally occurring coumestan wedelolactone has been previously shown to reduce growth of various cancer cells. So far, the growth-suppressing effect of wedelolactone has been attributed to the inhibition of the NFκB transcription factor and/or androgen receptors. We found that wedelolactone suppressed growth and induced apoptosis of androgen receptor-negative MDA-MB-231 breast cancer cells at concentrations that did not inhibit the NFκB activity. The cells responded to wedelolactone by the S and G2/M phase cell cycle arrest and induction of the DNA damage signaling. Wedelolactone interacted with dsDNA and inhibited the activity of DNA topoisomerase IIα. We conclude that wedelolactone can act as growth suppressor independently of NFκB and androgen receptors.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12027057
- 003
- CZ-PrNML
- 005
- 20161214104239.0
- 007
- ta
- 008
- 120816s2011 ie f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.canlet.2011.01.002 $2 doi
- 035 __
- $a (PubMed)21315506
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ie
- 100 1_
- $a Beneš, Petr $7 xx0208982 $u Department of Experimental Biology, Faculty of Science, Masaryk University, Czech Republic. pbenes@sci.muni.cz
- 245 10
- $a Inhibition of topoisomerase IIα: novel function of wedelolactone / $c Petr Benes, Lucia Knopfova, Filip Trcka, Alice Nemajerova, Diana Pinheiro, Karel Soucek, Miroslav Fojta, Jan Smarda
- 520 9_
- $a The naturally occurring coumestan wedelolactone has been previously shown to reduce growth of various cancer cells. So far, the growth-suppressing effect of wedelolactone has been attributed to the inhibition of the NFκB transcription factor and/or androgen receptors. We found that wedelolactone suppressed growth and induced apoptosis of androgen receptor-negative MDA-MB-231 breast cancer cells at concentrations that did not inhibit the NFκB activity. The cells responded to wedelolactone by the S and G2/M phase cell cycle arrest and induction of the DNA damage signaling. Wedelolactone interacted with dsDNA and inhibited the activity of DNA topoisomerase IIα. We conclude that wedelolactone can act as growth suppressor independently of NFκB and androgen receptors.
- 650 _2
- $a antigeny nádorové $x metabolismus $7 D000951
- 650 _2
- $a protinádorové látky $x farmakologie $7 D000970
- 650 _2
- $a apoptóza $x účinky léků $7 D017209
- 650 _2
- $a nádory prsu $x farmakoterapie $x enzymologie $x patologie $7 D001943
- 650 _2
- $a buněčný cyklus $x účinky léků $7 D002453
- 650 _2
- $a buňky - růstové procesy $x účinky léků $7 D048708
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a viabilita buněk $x účinky léků $7 D002470
- 650 _2
- $a kumariny $x farmakologie $7 D003374
- 650 _2
- $a poškození DNA $7 D004249
- 650 _2
- $a DNA-topoisomerasy typu II $x metabolismus $7 D004250
- 650 _2
- $a DNA vazebné proteiny $x antagonisté a inhibitory $x metabolismus $7 D004268
- 650 _2
- $a ELISA $7 D004797
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunoblotting $7 D015151
- 650 _2
- $a signální transdukce $7 D015398
- 650 _2
- $a inhibitory topoisomeras $x farmakologie $7 D059003
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Knopfová, Lucia $7 xx0208986 $u Department of Experimental Biology, Faculty of Science, Masaryk University, Czech Republic
- 700 1_
- $a Trčka, Filip $7 xx0228680 $u Department of Experimental Biology, Faculty of Science, Masaryk University, Czech Republic
- 700 1_
- $a Nemajerová, Alice $7 xx0079430 $u Department of Experimental Biology, Faculty of Science, Masaryk University, Czech Republic
- 700 1_
- $a Pinheiro, Diana $u Department of Experimental Biology, Faculty of Science, Masaryk University, Czech Republic
- 700 1_
- $a Souček, Karel $7 xx0140754 $u Department of Cytokinetics, Institute of Biophysics, Academy of Sciences of the Czech Republic, Brno, Czech Republic
- 700 1_
- $a Fojta, Miroslav, $d 1967- $7 xx0060599 $u Department of Biophysical Chemistry and Molecular Oncology, Institute of Biophysics, Academy of Sciences of the Czech Republic, Brno, Czech Republic
- 700 1_
- $a Šmarda, Jan, $d 1930-2021 $7 jk01130508 $u Department of Experimental Biology, Faculty of Science, Masaryk University, Czech Republic
- 773 0_
- $w MED00001044 $t Cancer letters $x 1872-7980 $g Roč. 303, č. 1 (2011), s. 29-38
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/21315506 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m $z 0
- 990 __
- $a 20120816 $b ABA008
- 991 __
- $a 20161214104257 $b ABA008
- 999 __
- $a ok $b bmc $g 949099 $s 784403
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2011 $b 303 $c 1 $d 29-38 $i 1872-7980 $m Cancer letters $n Cancer Lett $x MED00001044
- GRA __
- $a NS9600 $p MZ0
- LZP __
- $b NLK122 $a Pubmed-20120816/11/02
